Youssef Zeidan

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Youssef Zeidan sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting upper half by trial count

Youssef Zeidan: 1 sponsored US clinical trial, 1 recruiting.

Youssef Zeidan sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. The most-studied condition in this pipeline is ER+ Breast Cancer, with 1 trials.

Mid-pack sponsor footprint

Youssef Zeidan is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING NA

Breast Re-irradiation After Second Ipsilateral Lumpectomy

NCT06867484

Therapeutic Areas

ER+ Breast Cancer 1
Cancer of the Breast 1
Estrogen Receptor-positive Breast Cancer 1
HER2-Negative Breast Cancer 1
Breast Cancer 1
Cancer 1

What is open in the Youssef Zeidan pipeline

1 recruiting of 1 indexed (100% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: ER+ Breast Cancer (1 trial), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Youssef Zeidan: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Youssef Zeidan sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Youssef Zeidan1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Youssef Zeidan sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Youssef Zeidan sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Youssef Zeidan page

1 registered trials is a research-attention snapshot, not an endorsement of Youssef Zeidan or any single study.

  • 1 of Youssef Zeidan's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • ER+ Breast Cancer is the condition Youssef Zeidan studies most, compare against other sponsors active in the same condition before evaluating a specific study. See ER+ Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Youssef Zeidan pipeline card: 1 registered trials from official public datasets.Report a data error.